Although mutations in most CDKs are rarely observed, CDK12 mutations are observed in different cancer types (2.6% of all cases, enriched in ovarian and prostate cancer) which are often homozygous and lead to a loss function [29,30,31]. This evidence concerns the gene CDK12 and Familial prostate cancer.